N-(6-{2-[trimethylsilyl]ethynyl}pyridin-2-yl)acetamide | 914950-33-7

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N-(6-{2-[trimethylsilyl]ethynyl}pyridin-2-yl)acetamide
• 英文别名: N-(6-((trimethylsilyl)ethynyl)pyridine-2-yl)acetamide；N-[6-(2-trimethylsilylethynyl)pyridin-2-yl]acetamide
• CAS: 914950-33-7
• 化学式: C₁₂H₁₆N₂OSi
• 分子量: 232.357
• InChiKey: GRUFFHCSABGUCE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.27
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  42
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-(6-{2-[trimethylsilyl]ethynyl}pyridin-2-yl)acetamide 在 甲醇 、 potassium carbonate 作用下， 生成 N-(6-ethynylpyridin-2-yl)acetamide
  参考文献：
  名称：

  膦氨基-三唑基-吡啶 [PN(H)N] 的阳离子和中性 PdII 和 PtII 钳配合物：钳配体稳定的钯纳米颗粒及其催化内部炔成环成茚酮

  摘要：

  我们描述了基于三唑基-吡啶的氨基膦的合成，N -(二苯基膦基)-6-(1-苯基)-1 H- (1,2,3-三唑-4-基)吡啶-2-胺[2 ,6-{(PPh 2 )-N(H)(C 5 H 3 N)(C 2 HN 3 C 6 H 5 )}] [ 1 , PN(H)N 以下] 及其钯和铂络合物和它们的催化应用。1与 [M(COD)Cl 2 ]（M = Pd 或 Pt）反应得到阳离子络合物 [(MCl){PN(H)N}-κ 3 -P,N,N]Cl [M = Pd ( 2 )或Pt( 3 )]。或者，化合物2和3也通过用[M(COD)Cl 2处理[2,6-{H 2 N(C 5 H 3 N)(C 2 HN 3 C 6 H 5 )}]( A )来合成]（M = Pd 或 Pt），然后添加化学计量的 PPh 2 Cl 和 Et 3 N。中性脱芳构化络合物 [(MCl){PNN}-κ 3 -P,N,N] [M

  DOI：

  10.1021/acs.inorgchem.3c01273
• 作为产物：
  描述：

  2-氨基-6-溴吡啶 在 吡啶 、 4-二甲氨基吡啶 、 copper(l) iodide 、 四(三苯基膦)钯 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 48.0h， 生成 N-(6-{2-[trimethylsilyl]ethynyl}pyridin-2-yl)acetamide
  参考文献：
  名称：

  Synthesis and evaluation of aminopyridine derivatives as potential BACE1 inhibitors

  摘要：

  To identify a new non-peptidyl BACE1 inhibitor, we focused on the aminopyridine structure, which binds to the active sites of BACE1. Synthesis of aminopyridine derivatives and evaluation of inhibitory activity against rBACE1 are described. The 2-aminopyridine moiety and/or 3-methoxybenzaldehyde could be converted to terminal acetylene derivatives by the Sonogashira method. Sonogashira or Glaser cross-coupling reactions with the corresponding derivatives followed by hydrogenation could derive the designed compounds. Although inhibitory activities of the synthetic compounds against rBACE1 were weak, the aminopyridine motif has potential as a BACE1 inhibitor. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2015.10.007

文献信息

• Towards Allosteric Receptors – Synthesis of Resorcinarene-Functionalized 2,2′-Bipyridines and Their Metal Complexes
  作者：Holger Staats、Friederike Eggers、Oliver Haß、Frank Fahrenkrug、Jens Matthey、Ulrich Lüning、Arne Lützen

  DOI：10.1002/ejoc.200900642

  日期：2009.10

  Based on a first example of an allosteric hemicarcerand (1) we prepared four new 2,2′-bipyridines that carry resorcinarene moieties in a highly convergent manner. Upon coordination to suitable transition metal ions or their complexes these compounds undergo conformational changes in a way that they switch between “open” and “closed” forms (2, 3, and 4) or vice versa (5), thus, bringing together or

  基于变构 hemicarcerand (1) 的第一个例子，我们制备了四种新的 2,2'-联吡啶，它们以高度收敛的方式携带间苯二酚部分。在与合适的过渡金属离子或其配合物配位后，这些化合物会发生构象变化，它们在“开放”和“封闭”形式（2、3 和 4）之间切换（2、3 和 4），反之亦然（5），从而将或将中心联吡啶上的两个功能部分分开。在作为构象转换效应物的过渡金属络合物中，[Re(CO)5Cl] 和位阻 2,9-芳基化 1,10-菲咯啉的单体铜 (I) 络合物被证明是非常有效的。(© Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2009)
• 1,6-Dihydro-1,3,5,6-Tetraaza-as-indacene based tricyclic compounds and pharmaceutical compositions comprising same
  申请人：Pitts J. William

  公开号：US20060270654A1

  公开（公告）日：2006-11-30

  The present invention provides for tricyclic compounds having the formula (I), wherein R 1 , R 2 , R 5 , R 6 , R 7 , and R 8 are as described herein. The present invention further provides pharmaceutical compositions comprising such compounds, as well as the use of such compounds for treating inflammatory and immune diseases.

  本发明提供了具有式(I)的三环化合物，其中R1，R2，R5，R6，R7和R8如本文所述。本发明还提供了包含这种化合物的药物组合物，以及使用这种化合物治疗炎症和免疫性疾病的方法。
• 1,6-dihydro-1,3,5,6-tetraaza-as-indacene based tricyclic compounds and pharmaceutical compositions comprising same
  申请人：Bristol-Myers Squibb Company

  公开号：US07737279B2

  公开（公告）日：2010-06-15

  The present invention provides for tricyclic compounds having the formula (I), wherein R1, R2, R5, R6, R7, and R8 are as described herein. The present invention further provides pharmaceutical compositions comprising such compounds, as well as the use of such compounds for treating inflammatory and immune diseases.

  本发明提供了具有以下公式（I）的三环化合物，其中R1、R2、R5、R6、R7和R8如本文所述。本发明还提供了包括这种化合物的制药组合物，以及使用这种化合物治疗炎症和免疫性疾病的方法。
• 1,6-DIHYDRO-1,3,5,6-TETRAAZA-AS-INDACENE BASED TRICYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME
  申请人：Pitts William J.

  公开号：US20100210629A1

  公开（公告）日：2010-08-19

  The present invention provides for tricyclic compounds having the formula (I), wherein R 1 , R 2 , R 5 , R 6 , R 7 , and R 8 are as described herein. The present invention further provides pharmaceutical compositions comprising such compounds, as well as the use of such compounds for treating inflammatory and immune diseases.

  本发明提供了具有式（I）的三环化合物，其中R1、R2、R5、R6、R7和R8如本文所述。本发明还提供了包含这些化合物的药物组合物，以及使用这些化合物治疗炎症和免疫性疾病的方法。
• Synthesis and evaluation of aminopyridine derivatives as potential BACE1 inhibitors
  作者：Hiroyuki Konno、Taki Sato、Yugo Saito、Iori Sakamoto、Kenichi Akaji

  DOI：10.1016/j.bmcl.2015.10.007

  日期：2015.11

  To identify a new non-peptidyl BACE1 inhibitor, we focused on the aminopyridine structure, which binds to the active sites of BACE1. Synthesis of aminopyridine derivatives and evaluation of inhibitory activity against rBACE1 are described. The 2-aminopyridine moiety and/or 3-methoxybenzaldehyde could be converted to terminal acetylene derivatives by the Sonogashira method. Sonogashira or Glaser cross-coupling reactions with the corresponding derivatives followed by hydrogenation could derive the designed compounds. Although inhibitory activities of the synthetic compounds against rBACE1 were weak, the aminopyridine motif has potential as a BACE1 inhibitor. (C) 2015 Elsevier Ltd. All rights reserved.